The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Immune monitoring of phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
Mark R. Albertini
Research Funding - Merck Serono
Jacquelyn A Hank
No relevant relationships to disclose
Brian Christopher Gadbaw
No relevant relationships to disclose
Jordan Kostlevy
No relevant relationships to disclose
Jennifer Haldeman
No relevant relationships to disclose
Jacek Gan
No relevant relationships to disclose
KyungMann Kim
No relevant relationships to disclose
Jens C. Eickhoff
No relevant relationships to disclose
Stephen Gillies
Employment or Leadership Position - Merck Serono (U)
Consultant or Advisory Role - Merck Serono (U)
Paul M. Sondel
Research Funding - Merck Serono